Cotinga Pharmaceuticals (TSXV:COT) (COTQF) Starts Presentation at 30th Annual ROTH Conference
Cotinga Pharmaceuticals (TSX-V: COT) (OTCQB: COTQF) is a clinical-stage pharmaceutical company that uses proprietary artificial intelligence (“AI”) technologies to pursue a targeted and transformational method to treating cancer and other unmet medical needs. Cotinga's CHEMSAS® technology fast-tracks the discovery and development of novel drug therapies. The company's lead compound, COTI‐2, has demonstrated in preclinical data that it could potentially improve the treatment of cancers with mutations in the p53 gene. COTI‐2 is being evaluated for the treatment of gynecologic cancers and HNSCC in a phase 1 clinical trial. Cotinga has secured orphan drug status in the United States for COTI‐2…